Right now the bond market is not sending very many distress signals. But if the mood shifts, we could suddenly have many more bonds trading at yields that make them appealing to investors with the appetite for high risk/high reward.
While the overall market continues to ride higher, there are signs beneath the surface that suggest things could begin to turn. Taking lessons from a legendary investor, we look at how to avoid getting caught up in the exuberance.
In a world of constant change, one thing remains steady: Americans love for chocolate. Today we focus on the ultimate “forever stock.” Backed up by more than a century of brand power, this business will remain as relevant for our children and grandchildren as it was for our parents and grandparents.
Dear Biotech Frontiers Subscribers: We have two timely pieces of news to digest. 1. This past Friday, February 16, the Food and Drug Administration (“FDA”) granted Iovance Biotherapeutics’ (Nasdaq: IOVA) lifileucel therapy accelerated approval for advanced melanoma, making it the first and only tumor-infiltrating lymphocyte (“TIL”) treatment available for cancer. Lifileucel’s approval is an important
In the midst of the market tumult and a broken merger, this company’s bonds felt a sharp decline in price. For analyst Martin Fridson this distress has created a very appealing new opportunity.
While this company may not be familiar to many people, its iconic brands certainly are. But because of corporate missteps, the owner of these gear and apparel makers has hit hard times — which we now see as an opportunity
As a sector, biotech stocks perform differently than tech stocks, “forever stocks,” and certainly the blue chips… We asked biotech veteran Erez Kalir to explain, in his own words, how he finds the right stocks for our new advisory Biotech Frontiers.
In this issue of Biotech Frontiers, we’ll lay out why one doctor’s five decades of pioneering work in oncology has not been simply an academic exercise… but instead stands to transform the lives of many cancer patients and reward this company’s shareholders who have funded its development.
